ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

  • Abstract Number: 2486 • 2017 ACR/ARHP Annual Meeting

    Rituximab Is an Attractive Proposition to Treat Difficult Active RA in Indian (Asia) Patients: Initial Results of a Non Commercial Initiative Using an Initial Regimen of Two 500 Mg Infusions (fortnightly) and a Third 500 Mg Infusion at 6 Weeks in Case of Inadequate Response(ACR 50)

    Arvind Chopra1, KIRAN ADAM2, NACHIKET KULKARNI3, Anuradha Venugopalan4, Toktam Kainifard5 and Manjit Saluja6, 1Center for Rheumatic Diseases, Pune, India, Pune, India, 2Rheumatology physician, PUNE, India, 3MD, DNB, PUNE, India, 4Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, 5Rheumatology, Consultant research and Dietitian, Pune, India, 6Rheumatology, Co-ordinator Research, Pune, India

    Background/Purpose: Considering the huge burden of RA in India, the use of biologic DMARDs is miniscule. The major deterrents are cost, poor awareness and few…
  • Abstract Number: 39 • 2017 ACR/ARHP Annual Meeting

    Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment

    Zoltán Konthur1, Melvin Michael Wiemkes2, Thomas Häupl2, Gerd R. Burmester2 and Karl Skriner2, 1Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, 2Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany

    Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann-Rheum-Dis. 2005 Feb;64(2):246-52)…
  • Abstract Number: 366 • 2016 ACR/ARHP Annual Meeting

    Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy

    Mie Jin Lim1, Won Park2, Seong-Ryul Kwon3 and Kyong-Hee Jung4, 1Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, 2Medicine/Rheumatology, IN-HA University Hospital, Choong-Gu Incheon, Korea, Republic of, 3Center for Rheumatism, Inha University Hospital, Incheon, South Korea, 4Hospital for Rheumatic Disease, Hanyang Univ Medical Center, Seoul, South Korea

    Background/Purpose: We investigated change of bone turnover markers in peripheral blood before, 6 and 12 months after rituximab therapy in seropositive RA patients. Methods: Ten…
  • Abstract Number: 1580 • 2016 ACR/ARHP Annual Meeting

    Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry

    Leslie R Harrold1, Ani John2, Jennie Best2, Steve Zlotnick2, Chitra Karki3, YouFu Li4, Jeffrey D. Greenberg5 and Joel Kremer6, 1UMass Medical School, Worcester, MA, 2Genentech, Inc., South San Francisco, CA, 3Corrona, LLC, Southborough, MA, 4University of Massachusetts Medical School, Worcester, MA, 5New York University School of Medicine, New York, NY, 6The Center for Rheumatology, Albany Medical College, Albany, NY

    Background/Purpose: Patients with rheumatoid arthritis (RA) experience diminished quality of life and increased disability. Patient-reported outcomes (PROs) are important measures of response to therapy in…
  • Abstract Number: 1634 • 2016 ACR/ARHP Annual Meeting

    Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks

    Chang-Hee Suh1, Alfredo Berrocal Kasay2, Elias Chalouhi El-Khouri3, Pedro Miranda4, Ljubinka Bozic Majstorovic5, Slawomir Jeka6, Pawel Hrycaj7, Dmytro Rekalov8, Piotr Wiland9, Andreas Krause10, Istvan Szombati11, Anna Mihailova12, Ihor Hospodarskyy13, Mariusz Piotrowski14, Seong-Ryul Kwon15, Eun-Young Lee16, Dae-Hyun Yoo17, Won Park18, Seung-Cheol Shim19, Sang-Joon Lee20 and Taek S. Kwon20, 1Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of, 2ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, 3Clinica Internacional, Lima, Peru, 4Centro De Estudios Reumatológicos, Santiago, Chile, 5Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, 6Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland, 7Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, 8Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 9Uniwersytecki Szpital Kliniczny im. Jana Mikulicza- Radeckigo, Wroclaw, Poland, 10Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 11QUALICLINIC Kft., Budapest, Hungary, 12Orto clinic Ltd., Riga, Latvia, 13Ternopil State Medical University, Ternopil, Ukraine, 14Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland, Lublin, Poland, 15Internal Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, 16Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, 17Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 18Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 19Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 20CELLTRION, Inc., Incheon, South Korea

    Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Result from Phase 3…
  • Abstract Number: 1635 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks

    Dae-Hyun Yoo1, Ljubinka Bozic Majstorovic2, Alfredo Berrocal Kasay3, Elias Chalouhi El-Khouri4, Fedra Irazoque-Palazuelos5, Francisco Cons Molina6, Pedro Miranda7, Pavel Shesternya8, Francisco G. Medina-Rodriguez9, Piotr Wiland10, Slawomir Jeka11, Olena Garmish12, Pawel Hrycaj13, Dmytro Rekalov14, Natalia Fomina15, Devy Zisman16, Yong-Beom Park17, Young Mo Kang18, Chang-Hee Suh19, Seung Cheol Shim20, Sang Joon Lee21, Sung Young Lee22 and Won Park23, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, 3ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, 4Clinica Internacional, Lima, Peru, 5Centro de Invstigacion y Tratamiento Reumatologico S.C, Mexico City, Mexico, 6Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 7Centro De Estudios Reumatológicos, Santiago, Chile, 8State Budgetary Educational Institution of High Professional Education "Krasnoyarsk state medical university n.a. professor V.F.Voino-Yasenetsky" Ministry of Health of Russian Federation, Krasnoyarsk, Russian Federation, 9Biologics Especializados SA, Mexico City, Mexico, 10Uniwersytecki Szpital Kliniczny im. Jana Mikulicza- Radeckigo, Wroclaw, Poland, 11Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland, 12Institute of Cardiology named by M.D. Strazhesko NAMS of Ukraine, Kyiv, Ukraine, 13Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, 14Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 15Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation, 16The Lady Davis, Haifa, Israel, 17Dept of Internal Medicine, Severance Hospital, Seoul, Korea, The Republic of, 18Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of, 19Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of, 20Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 21CELLTRION, Inc., Incheon, South Korea, 22Clinical Planning Department, CELLTRION, Inc., Incheon, South Korea, 23Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea

    Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Result from Phase 3 Randomized Controlled Trial over 24…
  • Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting

    Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept

    Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Alain Cantagrel4, Bernard Combe5, Maxime Dougados6, RENE MARC FLIPO7, Olivier Vittecoq8, Thierry Schaeverbeke9, Isabelle Pane10, Jean Sibilia11, Xavier Mariette12 and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Epidemiology, Hotel Dieu, PARIS, France, 3Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 4Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 5Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 6Rheumatology, Paris Descartes University, Paris, France, 7Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 8INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 9Rheumatology, CHU Bordeaux, Bordeaux, France, 10Epidemiology, Hotel Dieu, Paris, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…
  • Abstract Number: 2117 • 2016 ACR/ARHP Annual Meeting

    B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab

    Geraldine Cambridge1, Rita A. Moura2, Venkat Reddy3 and Maria J. Leandro1, 1Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, 3Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function…
  • Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting

    Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis

    Duncan Porter1, C. S. Goodyear2, J. S. Nijjar1, Martina Messow3, Stefan Siebert1, Manikhandan Mudaliar4 and Iain B. McInnes5, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, 4Glasgow Polyomics Facility, University of Glasgow, Glasgow, United Kingdom, 5Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain

    Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…
  • Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting

    Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset

    Elizabeth M.A. Hensor1,2, Edward M. Vital1,2 and Paul Emery1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1].  However, there is significant heterogeneity in this group of patients for baseline clinical features…
  • Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting

    Rituximab Induced Serum Sickness: A Systematic Review

    Paras Karmacharya1, Dilli Poudel1, Ranjan Pathak1, Anthony Donato2, Sushil Ghimire1, Smith Giri3, Madan Aryal1 and Clifton O. Bingham III4, 1Internal Medicine, Reading Health System, WEST READING, PA, 2Internal medicine, Reading Health System, WEST READING, PA, 3Internal medicine, University of Tennessee Health Science Center, Memphis, TN, 4Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…
  • Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting

    Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register

    Alexander G.S. Oldroyd1, Deborah P.M. Symmons1, Lianne Kearsley-Fleet1, Kath Watson1, Mark Lunt2, Jamie Sergeant1, Kimme L. Hyrich1 and on behalf of the BSRBR-RA, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…
  • Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting

    Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis

    Javier Narváez1, Milagros Ricse2, Juan José Alegre3, Gloria Albert Espi3, Carmen Gomez Vaquero4, Helena Borrell Paños2, Eulalia Armengol2, Joan Miquel Nolla2, Susana Herrera5 and Maria Molina6, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 4Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, 5Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, 6Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
  • Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting

    B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens

    Geraldine Cambridge1, Lauren J. Lahey2, Maria J. Leandro1, William H. Robinson3 and Jeremy Sokolove4, 1Rheumatology, University College London, London, United Kingdom, 2Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 3VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA

    Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
  • Abstract Number: 1668 • 2015 ACR/ARHP Annual Meeting

    Patterns of Relapse in the Rheumatoid Arthritis Cohort Treated with Rituximab at University College London

    Elena Becerra, Geraldine Cambridge, Inmaculada de la Torre and Maria J. Leandro, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Patterns of relapse in the Rheumatoid Arthritis cohort treated with Rituximab at University College LondonBackground/Purpose: Two patterns of relapse were defined in the first studies…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology